CHDI
Huntington’s Disease Society of America endorses Enroll-HD
A statement from the Huntington's Disease Society of America New York, NY, February 21, 2014 -- The Huntington’s Disease Society of America (HDSA) is pleased to announce its endorsement of the Enroll-HD prospective registry stud ...Read More
CHDI Foundation and Genzyme enter agreement to develop novel virally delivered gene-silencing therapeutic for Huntington’s disease
New York, NY, February 21 2014 - CHDI Foundation, Inc. and Genzyme Corporation have entered into a collaboration to develop adeno-associated virus delivery of a novel gene silencing therapeutic approach for Huntington's disease. The agreed res ...Read More
Roche and Isis Pharmaceuticals form alliance for Huntington’s disease
Basel, Switzerland and Carlsbad, CA, USA Roche (SIX: RO, ROG; OTCQX: RHHBY) and Isis Pharmaceuticals, Inc (NASDAQ: ISIS) today announced that they have formed an alliance to develop treatments for Huntington’s disease (HD) based on Isis’ antis ...Read More
Huntington’s disease therapeutic and companion biomarker collaboration forged by KineMed, Isis Pharmaceuticals, and CHDI Foundation.
Emeryville, CA, KineMed, Inc., Isis Pharmaceuticals Inc. (NASDAQ: ISIS), and CHDI Foundation, Inc., announced today that they are collaborating to utilize KineMed’s translational biomarker platform with Isis’s antisense therapeutic program for H ...Read More
CHDI Foundation continues collaboration with Medtronic to advance siRNA therapeutics to treat Huntington’s disease
New York City, CHDI Foundation, Inc. has announced it will continue its collaboration with Medtronic, Inc. (NYSE: MDT) to advance a novel drug-device combination therapy for the treatment of Huntington’s disease (HD). This therapeutic approach uses ...Read More
Sangamo BioSciences announces FIRST presentation of Data from ZFP Therapeutic® for Huntington’s disease at 2012 Annual Meeting of Society for Neuroscience
Richmond, California, Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its program with Shire AG (LSE: SHP, NASDAQ: SHPG) to develop a novel ZFP Therapeutic approach to Huntington’s disease (HD), an inherited progressive neurodegen ...Read More
Proteome Sciences to collaborate with CHDI Foundation on Huntington’s disease research
London, UK. Proteome Sciences plc (Proteome) has announced that they will collaborate with CHDI Foundation, Inc. on a systems biology project regarding Huntington’s disease. Initially, Proteome will provide its PS Biomarker Services™ protein pro ...Read More
GNS Healthcare And CHDI Foundation Collaborate To Build Computer Model Of Huntington’s Disease
Cambridge, MA, and New York, NY – GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with CHDI Found ...Read More
Thomson Reuters Partners with CHDI Foundation to Develop Systems Biology Tools for Huntington’s Disease
Philadelphia, PA, The Intellectual Property & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced a collaboration with CHDI Foundation, Inc. to develop syste ...Read More
Lundbeck and CHDI Foundation announce research collaboration to investigate candidate therapy for Huntington’s disease
Deerfield, Ill., – CHDI Foundation, Inc. and Lundbeck today announced a research collaboration to investigate a targeted therapy for Huntington’s disease (HD). Currently, no treatment exists to slow or halt the progression of HD,1 a ...Read More